(S)-((S)-2-tert-butoxycarbonylamino-3,3-dimethylbutyrylamino)cyclohexylacetic acid methyl ester | 862119-00-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-((S)-2-tert-butoxycarbonylamino-3,3-dimethylbutyrylamino)cyclohexylacetic acid methyl ester
• 英文别名: (2-tert-butoxycarbonylamino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester；Boc-Gly(tBu)-Chg-OMe；methyl (2S)-2-cyclohexyl-2-[[(2S)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]acetate
• CAS: 862119-00-4
• 化学式: C₂₀H₃₆N₂O₅
• 分子量: 384.516
• InChiKey: ZRVLLMZWGUONGV-LSDHHAIUSA-N

物化性质

• 沸点：
  515.8±30.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  93.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-((S)-2-tert-butoxycarbonylamino-3,3-dimethylbutyrylamino)cyclohexylacetic acid methyl ester 在 三乙基硅烷 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (S)-2-{[trans-2-{(S)-1-[((S)-cyclohexyl(methoxycarbonyl)methyl)carbamoyl]-2,2-dimethylpropylcarbamoyl}-4-(7-methoxy-2-phenylquinolin-4-yloxy)cyclopent-1-enecarbonyl]amino}butyric acid
  参考文献：
  名称：

  Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: Discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-l-hydroxyproline bioisostere

  摘要：

  Potent tetrapeptidic inhibitors of the HCV NS3 protease have been developed incorporating 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a new N-acyl-L-hydroxyproline mimic. The hydroxycyclopentene template was synthesized in eight steps from commercially available, (syn)-tetrahydrophthalic anhydride. Three different amino acids were explored in the PI-position and in the P2-position the hydroxyl group of the cyclopentene template was substituted with 7-methoxy-2-phenyl-quinolin-4-ol. The P3/P4-positions were then optimized from a set of six amino acid derivatives. All inhibitors were evaluated in an in vitro assay using the full-length NS3 protease. Several potent inhibitors were identified, the most promising exhibiting a K-i value of 1.1 nM. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.044
• 作为产物：
  描述：

  methyl (S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexyl acetate 在 三乙基硅烷 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 (S)-((S)-2-tert-butoxycarbonylamino-3,3-dimethylbutyrylamino)cyclohexylacetic acid methyl ester
  参考文献：
  名称：

  Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: Discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-l-hydroxyproline bioisostere

  摘要：

  Potent tetrapeptidic inhibitors of the HCV NS3 protease have been developed incorporating 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a new N-acyl-L-hydroxyproline mimic. The hydroxycyclopentene template was synthesized in eight steps from commercially available, (syn)-tetrahydrophthalic anhydride. Three different amino acids were explored in the PI-position and in the P2-position the hydroxyl group of the cyclopentene template was substituted with 7-methoxy-2-phenyl-quinolin-4-ol. The P3/P4-positions were then optimized from a set of six amino acid derivatives. All inhibitors were evaluated in an in vitro assay using the full-length NS3 protease. Several potent inhibitors were identified, the most promising exhibiting a K-i value of 1.1 nM. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.044

文献信息

• UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Chen Dawei

  公开号：US20090082261A1

  公开（公告）日：2009-03-26

  The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R 1 -R 9 , J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  本发明提供了含有尿素的多肽化合物，其结构如式I所示，以及它们的药物盐和 hydrates（水合物）。 变量T，R1-R9，J，L，M，Y，Z，m，n和t在此文中定义。式I中的某些化合物作为抗病毒剂是有用的。本文中公开的某些含尿素的多肽化合物是病毒复制的强效和/或选择性抑制剂，尤其是丙型肝炎病毒复制。本发明还提供了包含一个或多个含尿素多肽化合物以及一个或多个药物可接受载体、辅料或稀释剂的药物组合物。这样的药物组合物可以仅含有一个含尿素多肽化合物作为唯一的活性成分，也可以包含一个含尿素多肽化合物与一个或多个其他药物活性成分的组合。本发明还提供了治疗哺乳动物中病毒感染的方法，包括丙型肝炎感染。
• HCV NS-3 serine protease inhibitors
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：EP1881001A1

  公开（公告）日：2008-01-23

  HCV inhibitors, compositions comprising these compounds as active ingredient, as well as processes for preparing these compounds, having the formula I wherein A is

  HCV抑制剂，包含这些化合物作为活性成分的组合物，以及制备这些化合物的过程，其化学式为I，其中A是。
• Site-Selective δ-C(sp³ )−H Alkylation of Amino Acids and Peptides with Maleimides via a Six-Membered Palladacycle
  作者：Bei-Bei Zhan、Ya Li、Jing-Wen Xu、Xing-Liang Nie、Jun Fan、Liang Jin、Bing-Feng Shi

  DOI：10.1002/anie.201801445

  日期：2018.5.14

  report on the site‐selective δ‐C(sp3)−H alkylation of amino acids and peptides with maleimides via a kinetically less favored six‐membered palladacycle in the presence of more accessible γ‐C(sp3)−H bonds. Experimental studies revealed that C−H bond cleavage occurs reversibly and preferentially at γ‐methyl over δ‐methyl C−H bonds while the subsequent alkylation proceeds exclusively at the six‐membered

  未活化的C（sp 3）-H键的位点选择性官能化仍然是有机合成中的最大挑战之一。在此，我们报道了在动力学上较不受欢迎的六元palladacycle在较易接近的γ-C（sp 3）存在下，氨基酸和肽与马来酰亚胺的位点选择性δ-C（sp 3）-H烷基化反应。）-H键。实验研究表明，CH键断裂可逆地发生在γ-甲基上，而不是δ-甲基CH键上，而随后的烷基化仅在由δ-CH活化产生的六元palladacycle上进行。选择性可以用科廷-汉密特原理来解释。这种烷基化与各种寡肽的出色相容性使该程序对于后期肽修饰很有价值。值得注意的是，该过程也是通过C（sp 3）-H活化进行的第一个钯（II）催化的Michael型烷基化反应。
• HCV NS-3 Serine Protease Inhibitors
  申请人：Rosenquist Asa

  公开号：US20100003216A1

  公开（公告）日：2010-01-07

  Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus sych as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

  式中的变量如规范中所定义，可以抑制黄热病病毒(NS3蛋白酶)等黄病毒的蛋白酶，如丙型肝炎病毒(HCV)。这些化合物包括一个新的链接，连接一个杂环P2单位和那些离原生底物的名义剪切位点更远的抑制剂部位，该链接将离剪切位点远侧的肽键的方向与靠近剪切位点的肽键的方向相反。
• Hcv ns-3 serine protease inhibitors
  申请人：Rosenquist Asa

  公开号：US20070161574A1

  公开（公告）日：2007-07-12

  Compounds of the formula where the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

  式子中的变量如规范所定义，能够抑制类黄病毒的NS3蛋白酶，例如丙型肝炎病毒（HCV）。这些化合物包括一种新颖的连接方式，连接了一个杂环P2单元和抑制剂更远离天然底物裂解位点的部分，该连接方式反转了远离裂解位点的肽键方向相对于靠近裂解位点的肽键方向。